Optimism regarding the use of RNA/DNA hybrids to repair genes at high efficiency
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 72 KB
- Volume
- 1
- Category
- Article
- ISSN
- 1099-498X
No coin nor oath required. For personal study only.
✦ Synopsis
obtained his MD degree from the University of Minnesota in 1964. In 1966 he moved to Bethesda, for what eventually became 32 years at the National Institutes of Health where he developed his career long interest in the investigation and treatment of patients with primary immunode®ciency disease. In 1990, he was the Principal Investigator of the initial human gene therapy trial which used retroviral vectors to transfer a normal ADA cDNA into the peripheral blood T cells of two girls with Severe Combined Immunode®ciency (SCID). His laboratory has developed gene therapies for AIDS and cancer including the ®rst clinical trial testing the strategy of inserting the herpes thymidine kinase (HSV-tk) suicide gene' into recurrent brain tumors. In 1998, Dr. Blaese was appointed Chief Scienti®c Of®cer of Kimeragen, where he is pursuing his work on the correction of genetic disorders using a gene repair system based on the use of chimeric DNA/RNA oligonucleotides. In his own words he has been totally seduced by this technology'. Dr. Blaese talked to The Journal of Gene Medicine, about the early results achieved using this approach and its prospects for the future.
JGM: Could you describe the structure of a chimeric RNA/DNA oligonucleotide?